[HTML][HTML] Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19

…, A Letkeman, J Dean, D Haug, J Breeze, R Traylor… - MedRxiv, 2020 - ncbi.nlm.nih.gov
Background: Mucosal immunity, including secretory IgA (sIgA), plays an important role in
early defenses against respiratory pathogens. Salivary testing, the most convenient way to …

Virologic efficacy of casirivimab and imdevimab COVID-19 antibody combination in outpatients with SARS-CoV-2 infection: a phase 2 dose-ranging randomized …

…, M Ramgopal, B Jacobs, T Chang, R Traylor… - JAMA Network …, 2022 - jamanetwork.com
Importance The monoclonal antibody combination of casirivimab and imdevimab reduced
viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous (IV…

Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.(preprint)

…, AF Letkeman, J Dean, D Haug, J Breeze, R Traylor… - 2020 - pesquisa.bvsalud.org
Background: Mucosal immunity, including secretory IgA (sIgA), plays an important role in
early defenses against respiratory pathogens. Salivary testing, the most convenient way to …

COVID-19 therapeutics for nonhospitalized patients

RT Gandhi, PN Malani, C Del Rio - Jama, 2022 - jamanetwork.com
Substantial progresshas been made in therapeutics for nonhospitalizedpatientswithCOVID-19,
butsupplyofand access to treatment remain limited. This Viewpoint summarizes currently …

Realizing the potential of anti–SARS-CoV-2 monoclonal antibodies for COVID-19 management

JZ Li, RT Gandhi - Jama, 2022 - jamanetwork.com
The phases of SARS-CoV-2 infection may be viewed along a spectrum. 1 Following
exposure, patients may have asymptomatic infection in which they test positive for the virus by …

Monoclonal antibodies for COVID-19

EC Lloyd, TN Gandhi, LA Petty - Jama, 2021 - jamanetwork.com
There are several approved treatments for coronavirus disease 2019 (COVID-19) in hospitalized
patients but few for patients who are not sick enough to be hospitalized. Monoclonal …

Questions remain about who will get monoclonal antibodies for COVID-19 preexposure prophylaxis

R Rubin - Jama, 2022 - jamanetwork.com
“AZD7442, AZD7442, AZD7442.” He finally hit pay dirt December 8, when
hediscoveredthattheUSFoodandDrugAdministration had authorized AstraZeneca’s long-acting …

Keith Couper, PhD Bronwen A. Connolly, PhD

DF McAuley - 2022 - jamanetwork.com
1. Perkins GD, Ji C, Connolly BA, et al; RECOVERY-RS Collaborators. Effect of noninvasive
respiratory strategies on intubation or mortality among patients with acute hypoxemic …

How men can be better allies for developing women leaders

A Townsend, SR Madsen… - Handbook of Research on …, 2024 - elgaronline.com
Over the last several decades, academic research and the popular press have brought
attention to the lack of gender parity in the workforce (Madsen & Scribner, 2017). While the …

[BOOK][B] I. Studies directed towards the total synthesis of nocathiacin III. II. The development of a new synthetic technology for the construction of N-hydroxyindoles …

AA Estrada - 2008 - search.proquest.com
The nocathiacins are a family of three thiopeptide antibiotics that posses remarkable
biological activity and operate with a mechanism of action that involves binding to rRNA and …